Beylerli, Ozal,
Gareev, Ilgiz,
Musaev, Elmar,
Roumiantsev, Sergey,
Chekhonin, Vladimir,
Ahmad, Aamir,
Chao, Yuan,
Yang, Guang (2025) /MEK/ERK pathway inhibitors, IDH mutation inhibitors, immune checkpoint inhibitors, and CAR-T
cell therapies
Timasheva, Yanina,
Kochetova, Olga,
Balkhiyarova, Zhanna,
Korytina, Gulnaz,
Prokopenko, Inga,
Nouwen, Arie (2025) , neurotransmitters, and β-
cell function, to develop a prognostic tool for MetS risk. Methods: We genotyped 40 genetic
determination of glial fibrillary acidic protein (GFAP) and anti-apoptotic B-
cell lymphoma-2 protein (Bcl-2
Fedorova, Yu. Yu.,
Aminova, E.T.,
Faishanova, R.R.,
Zagitov, I.R.,
Romanova, A.R.,
Nurgalieva, A.Kh.,
Andreeva, E.A.,
Darvish, M.,
Khusnutdinova, E.K.,
Prokofyeva, D.S. (2025) development, the degree of
cell differentiation, the occurrence of distant and regional metastases, as well
of DEGs was performed using Gene Ontology (GO) resources, and the
cell signaling pathway analysis of DEGs